KORU Medical Systems Joins Subcutaneous Drug Development & Delivery Consortium
October 05 2022 - 6:01AM
Business Wire
KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU
Medical”), a leading medical technology company focused on the
development of innovative and easy-to-use home infusion solutions,
today announced its membership in the Subcutaneous (SC) Drug
Development & Delivery Consortium (the “Consortium”), making it
one of the first device companies to be added to the
Consortium.
“The Consortium creates an important forum to identify and
address key challenges and opportunities across the SC field,” said
Linda Tharby, KORU Medical’s President and CEO. “Key industry
experts can collaborate on issues at the clinical, regulatory, and
commercial level and work towards advancing the SC market and
creating the best outcomes for patients. I am excited for KORU
Medical’s membership as one of the first device companies and look
forward to advancing SC drug delivery.”
The Consortium was convened in 2018 as a community of
well-recognized industry experts with decades of experience in the
pharmaceutical drug delivery, device development, and
commercialization space. The Consortium was built upon a strong
desire for clear and transparent evidence-based communication of
existing SC technologies and information. The Consortium’s mission
is to identify current and future unmet medical needs within a
dynamic SC drug delivery and development environment to transform
patient care and improve patient outcomes. As a member, KORU
Medical will contribute to advancing understanding of patient
preference for SC therapy and the clinical trial strategy and
technology for high-volume SC drugs. KORU Medical was one of the
first companies to develop technology for SC biologics with volumes
above 5mL, and its Freedom System is used by over 25,000 patients
today to receive SC therapy. KORU Medical is established as the
market leader in above 10mL and will bring this deep expertise in
patient experience and subcutaneous injection technology to the
Consortium.
About KORU Medical KORU Medical develops, manufactures, and
commercializes innovative and easy-to-use specialty infusion
solutions that improve quality of life for patients around the
world. The FREEDOM Syringe Infusion System (the “Freedom System”)
currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion
Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous
Safety Needle Sets™. These devices are used for infusions
administered in the home and alternate care settings. For more
information, please visit www.korumedical.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221005005323/en/
Investor Contact: Greg Chodaczek 347-620-7010
investor@korumedical.com
KORU Medical Systems (NASDAQ:KRMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
KORU Medical Systems (NASDAQ:KRMD)
Historical Stock Chart
From Apr 2023 to Apr 2024